Vanguard Global Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Vanguard Global Advisers's FDMT Position: Q3 2026 in Review
Vanguard Global Advisers increased its 4D Molecular Therapeutics (FDMT) stake by 102% in Q3 2026, buying an estimated $200K and bringing the position to 30,430 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2149.
Vanguard Global Advisers first reported a position in FDMT in Q1 2026 and has held it in 3 quarters since. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Vanguard Global Advisers held 30,430 shares of 4D Molecular Therapeutics worth $435K as of Q3 2026.
- Vanguard Global Advisers bought 15,346 4D Molecular Therapeutics shares in Q3 2026, an estimated $200K.
- 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2149 holding.
- Vanguard Global Advisers first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.